Fig. 6
Validation of LAMP2 in resting CD4+ T cells using mass spectrometry-based MRM technology. A. LC-MS profile of the peptide from LAMP2; B. LC-MS profile of the peptide from β-actin; C. The relative peak area of LAMP2 to β-actin. Three groups were enrolled, including healthy volunteers, HIV-1 infected patients with a virus load < 50 copies/mL, and > 105 copies/mL (n = 5/group). Each group consisted of five samples, and each sample was analyzed twice by LC-MS. T-tests, and ANOVA analysis were used for the comparison of two groups, and three groups, respectively. **, and *** represent significance levels of p < 0.01, and 0.005, respectively